On May 12, 2023 Panolos Bioscience reported that the company signed a consulting contract with MediRama (CEO Moon Hanlim) on May 3 (Presentation, Panolos Bioscience, MAY 12, 2023, View Source [SID1234633691]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Based on a high level of understanding of clinical development, MediRama provides a successful clinical performance strategy by acting as Biotech’s clinical development headquarters.

Through this contract, Panolos commenced MediRrama to consult on clinical development for the successful clinical performance of PB101/PB102, a key pipeline, and appointed CEO Moon Hanlim as a SAB (Scientific Advisory Board) to solidify a close partnership to devise Panolos’ pipeline portfolio operation strategy.

On May 12, 2023 Oncolys BioPharma reported that non-consolidated Financial Results for the Three Months Ended March 31, 2023 (Press release, Oncolys BioPharma, MAY 12, 2023, View Source [SID1234632948]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 12, 2023 Otsuka reported its Consolidated Financial Results for the First Quarter of the Fiscal Year Ending December 31, 2023 (Press release, Otsuka, MAY 12, 2023, View Source [SID1234632880]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 12, 2023 Evotec reported its quarterly statement first quarter 2023 (Filing, 3 mnth, MAR 31, Evotec, 2023, MAY 12, 2023, View Source [SID1234631876]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As previously disclosed, on April 1, 2022, Oncorus, Inc. (the "Company") entered into a Loan and Security Agreement with K2 HealthVentures LLC, as lender and administrative agent, and Ankura Trust Company, LLC, as collateral agent for the lender (the "Loan Agreement"), which enabled the Company to borrow up to an aggregate of $45.0 million of principal in loan terms upon the achievement of certain time-based and regulatory milestones. The Company borrowed the first tranche of $20.0 million under the Loan Agreement concurrently with its execution (Filing, 8-K, Oncorus, DEC 12, 2023, View Source [SID1234631851]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 12, 2023, the Company paid in full all of its outstanding obligations and other fees due under the Loan Agreement, consisting of $20.0 million in principal and approximately $1.6 million of accrued interest and related fees and expenses. Following the repayment, the Loan Agreement was terminated in its entirety.